FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103107661> ?p ?o ?g. }

• W2103107661 endingPage "e266" @default.
• W2103107661 startingPage "e266" @default.
• W2103107661 abstract "Background: The adalimumab (ADA) treatment is an available option for pediatric CD. The published experience on ADA treatment in pediatric Crohn's disease (CD) is limited. Objectives: We reported a multicenter evaluation of the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition about ADA efficacy and safety after IFX failure in pediatric CD. Methods: A retrospective study recorded demographic data, growth parameters, clinical response (PCDAI score), endoscopic findings (CDEIS score) and adverse events at 6 m and at the patient's last follow up. Results: 42 pts were evaluated at the ADA start, after IFX therapy. The main characteristics were: mean age 14.6 y, 22 F, 75% moderate-severe disease (mean PCDAI 25). 52% CRP value positive; mean time from diagnosis 3.8 y (range 5 m–11 y). Only one needed steroids. At 6 m 61% complete clinical remission, 13% partial clinical remission 26% active disease (mean PCDAI 12). 42% had CRP positive values. Mean follow up time after ADA start was 14 m. At the last follow up: At maximum follow up, 62% of pts were in clinical remission, 6% in partial clinical remission and 32% pts had active disease. The mean PCDAI value at the ADA start was 24.5 (median 23.7), at 6 months was 12.8 (median 10) and at the last follow up 13.7 (median 10). PCDAI decrements were statistically significant (p < 0.01). At maximum follow up 42% of pts CRP values were positive. At last follow up endoscopic evaluation was available in 54% of pts and documented mucosal healing in 65%, mild-moderate lesions in 10% and severe lesions in 25%. Not significant difference in statural growth and weight gain was detected from the ADA start. Adverse events were one case of meningitis and one of medulloblastoma treated with IFX and ADA (18 m). In univariate analysis no prognostic factors were found (sex, age and disease extension, reasons for IFX stop) except for the combined therapy IFX and immunomodulators and disease duration > 3 y before ADA start that were negatively correlated with the final PCDAI values (p < 0.01). Conclusions: In our experience, ADA therapy has been a good alternative, when IFX did not work, in determining clinical and endoscopic remission (65% of pts). Treatment efficacy with anti-TNF agents should be balanced against infection risk and possible onset of cancer." @default.
• W2103107661 created "2016-06-24" @default.
• W2103107661 creator A5003114766 @default.
• W2103107661 creator A5004951987 @default.
• W2103107661 creator A5011938116 @default.
• W2103107661 creator A5014046124 @default.
• W2103107661 creator A5018231363 @default.
• W2103107661 creator A5020709258 @default.
• W2103107661 creator A5045878668 @default.
• W2103107661 creator A5048146846 @default.
• W2103107661 creator A5055009090 @default.
• W2103107661 creator A5055256352 @default.
• W2103107661 creator A5058702991 @default.
• W2103107661 creator A5066290442 @default.
• W2103107661 creator A5090239706 @default.
• W2103107661 creator A5091549517 @default.
• W2103107661 date "2013-09-01" @default.
• W2103107661 modified "2023-10-16" @default.
• W2103107661 title "Evaluation of adalimumab (ADA) therapy after infliximab (IFX) failure in pediatric Crohn disease (CD)" @default.
• W2103107661 doi "https://doi.org/10.1016/j.dld.2013.08.147" @default.
• W2103107661 hasPublicationYear "2013" @default.
• W2103107661 type Work @default.
• W2103107661 sameAs 2103107661 @default.
• W2103107661 citedByCount "1" @default.
• W2103107661 countsByYear W21031076612016 @default.
• W2103107661 crossrefType "journal-article" @default.
• W2103107661 hasAuthorship W2103107661A5003114766 @default.
• W2103107661 hasAuthorship W2103107661A5004951987 @default.
• W2103107661 hasAuthorship W2103107661A5011938116 @default.
• W2103107661 hasAuthorship W2103107661A5014046124 @default.
• W2103107661 hasAuthorship W2103107661A5018231363 @default.
• W2103107661 hasAuthorship W2103107661A5020709258 @default.
• W2103107661 hasAuthorship W2103107661A5045878668 @default.
• W2103107661 hasAuthorship W2103107661A5048146846 @default.
• W2103107661 hasAuthorship W2103107661A5055009090 @default.
• W2103107661 hasAuthorship W2103107661A5055256352 @default.
• W2103107661 hasAuthorship W2103107661A5058702991 @default.
• W2103107661 hasAuthorship W2103107661A5066290442 @default.
• W2103107661 hasAuthorship W2103107661A5090239706 @default.
• W2103107661 hasAuthorship W2103107661A5091549517 @default.
• W2103107661 hasBestOaLocation W21031076611 @default.
• W2103107661 hasConcept C126322002 @default.
• W2103107661 hasConcept C141071460 @default.
• W2103107661 hasConcept C167135981 @default.
• W2103107661 hasConcept C197934379 @default.
• W2103107661 hasConcept C2776848118 @default.
• W2103107661 hasConcept C2777138892 @default.
• W2103107661 hasConcept C2779134260 @default.
• W2103107661 hasConcept C2779280984 @default.
• W2103107661 hasConcept C2780132546 @default.
• W2103107661 hasConcept C41260117 @default.
• W2103107661 hasConcept C71924100 @default.
• W2103107661 hasConcept C90924648 @default.
• W2103107661 hasConceptScore W2103107661C126322002 @default.
• W2103107661 hasConceptScore W2103107661C141071460 @default.
• W2103107661 hasConceptScore W2103107661C167135981 @default.
• W2103107661 hasConceptScore W2103107661C197934379 @default.
• W2103107661 hasConceptScore W2103107661C2776848118 @default.
• W2103107661 hasConceptScore W2103107661C2777138892 @default.
• W2103107661 hasConceptScore W2103107661C2779134260 @default.
• W2103107661 hasConceptScore W2103107661C2779280984 @default.
• W2103107661 hasConceptScore W2103107661C2780132546 @default.
• W2103107661 hasConceptScore W2103107661C41260117 @default.
• W2103107661 hasConceptScore W2103107661C71924100 @default.
• W2103107661 hasConceptScore W2103107661C90924648 @default.
• W2103107661 hasLocation W21031076611 @default.
• W2103107661 hasOpenAccess W2103107661 @default.
• W2103107661 hasPrimaryLocation W21031076611 @default.
• W2103107661 hasRelatedWork W153197085 @default.
• W2103107661 hasRelatedWork W1588288904 @default.
• W2103107661 hasRelatedWork W1963997208 @default.
• W2103107661 hasRelatedWork W2000908943 @default.
• W2103107661 hasRelatedWork W2069757747 @default.
• W2103107661 hasRelatedWork W2085326056 @default.
• W2103107661 hasRelatedWork W2276170289 @default.
• W2103107661 hasRelatedWork W2423402760 @default.
• W2103107661 hasRelatedWork W2755604283 @default.
• W2103107661 hasRelatedWork W2794420180 @default.
• W2103107661 hasVolume "45" @default.
• W2103107661 isParatext "false" @default.
• W2103107661 isRetracted "false" @default.
• W2103107661 magId "2103107661" @default.
• W2103107661 workType "article" @default.